Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome
Authors' conclusion
Setmelanotide treatment is associated with improvement of MASLD independent of BMI reduction as well as increased glomerular filtration rate in BBS.
Study context
- Population
- Patients >6 years with genetically confirmed Bardet-Biedl syndrome (BBS), obesity and/or hyperphagia; mean age 19.2 years; all with MASLD (54% S3, 23% each S1 and S2)
- Participants
- 26 patients
- Exposure
- Before vs after 6 months of setmelanotide
- Outcome
- Short-term impact on MASLD and kidney function
- Follow-up
- 6 months
Methodological detailsmonocentric, real-world data, Conducted June–December 2023
- Monocentric
- Real-world data
- Conducted June–December 2023
Main finding
As reported in the abstract
Change after setmelanotide
eGFR increase up to
10.1 (mL/min/1.73 m²; 95% CI [4.3; 15.9])
Attenuation imaging (ATI) change
−0.14 (dB/cm/MHZ; 95% CI [−0.17; −0.11])
Resolution of MASLD or stabilization at grade S1
85%
Observational data: associations, not effects.
Further findings
Other parameters · 6 months
- Body mass index (BMI) z-score change
- −0.5 (95% CI [−0.6; −0.3])
- Hyperphagia score change
- −12.3 (95% CI [−15.5; −9.0])
- Total body fat change
- −3.1% (95% CI [−5.7; −0.5])
Original publication
Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome. J Clin Endocrinol Metab. Published 4 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →